Ensoma Announces First Patient Dosed in Phase 1/2 Clinical Trial of EN-374 for Treatment of X-CGD

Ensoma has dosed the first patient in its Phase 1/2 clinical trial of EN-374, an in vivo HSC-directed gene insertion therapy for X-linked chronic granulomatous disease (X-CGD). This marks the first clinical evaluation of such a therapy, aiming to restore immune function in X-CGD patients. The trial will assess safety, tolerability, and efficacy, with the FDA granting rare pediatric disease and orphan drug designations for EN-374. Ensoma's platform could also impact oncology and sickle cell disease treatments.